INFLATION REDUCTION ACT “PILL PENALTY” AND SMALL-MOLECULE INNOVATION: SIGNALS FROM INVESTMENT, PIPELINES, AND POST-APPROVAL RESEARCH?
Author(s)
Onur Baser, MA, MS, PhD1, Katarzyna Rodchenko, MA, MPH2, Huseyin Yuce, MS, PhD3;
1City University of New York (CUNY), Graduate School of Public Health, New York, NY, USA, 2Columbia Data Analytics, New York, NY, USA, 3City University of New York (CUNY), Mathematics, New York, NY, USA
1City University of New York (CUNY), Graduate School of Public Health, New York, NY, USA, 2Columbia Data Analytics, New York, NY, USA, 3City University of New York (CUNY), Mathematics, New York, NY, USA
OBJECTIVES: This analysis evaluated how the Inflation Reduction Act (IRA)’s shorter price-negotiation window affects investment, research and development (R&D) pipelines, and post-approval evidence generation for small-molecule drugs compared with biologics.
METHODS: A policy-focused analysis synthesized public data on US Food and Drug Administration approvals, venture capital (VC) flows, and industry-funded post-approval trials, combined with stakeholder survey findings on perceived IRA impacts. The READ method (Ready materials, Extract data, Analyze data, Distill findings) was used to structure evidence extraction from policy documents, investment reports, and corporate disclosures, and to quantify pre- vs post-IRA changes for small molecules vs biologics.
RESULTS: Aggregate VC investments in small-molecule startups declined by approximately 68% post-IRA (from approximately USD $2.0 billion to USD $640 million), and 2024 biologics investment was roughly 10-fold higher than for small molecules. Industry-sponsored post-approval trials decreased by 38.4% overall, with a sharper 47.3% drop for small molecules vs 32.9% for biologics, and oncology post-approval research showed a particularly pronounced decline for small-molecules. Survey data indicated that 77% of investors view the IRA’s “pill penalty” as disincentivizing small-molecule R&D, and 87% of pharmaceutical executives reported altering R&D or launch plans, including shifting away from Medicare-reliant indications and early-stage small-molecule programs. These trends suggest potential long-term reductions in oral and other small-molecule treatment options for elderly and chronic-disease populations, despite near-term improvements in affordability under Medicare Part D caps.
CONCLUSIONS: Early post-IRA signals indicate that shorter effective exclusivity for small molecules is associated with sizeable reductions in small-molecule investment and post-approval research and strategic shifts away from small-molecule pipelines. Policymakers may need to consider adjustments, such as harmonizing negotiation timelines across modalities, to preserve incentives for small-molecule innovation while maintaining Medicare affordability goals.
METHODS: A policy-focused analysis synthesized public data on US Food and Drug Administration approvals, venture capital (VC) flows, and industry-funded post-approval trials, combined with stakeholder survey findings on perceived IRA impacts. The READ method (Ready materials, Extract data, Analyze data, Distill findings) was used to structure evidence extraction from policy documents, investment reports, and corporate disclosures, and to quantify pre- vs post-IRA changes for small molecules vs biologics.
RESULTS: Aggregate VC investments in small-molecule startups declined by approximately 68% post-IRA (from approximately USD $2.0 billion to USD $640 million), and 2024 biologics investment was roughly 10-fold higher than for small molecules. Industry-sponsored post-approval trials decreased by 38.4% overall, with a sharper 47.3% drop for small molecules vs 32.9% for biologics, and oncology post-approval research showed a particularly pronounced decline for small-molecules. Survey data indicated that 77% of investors view the IRA’s “pill penalty” as disincentivizing small-molecule R&D, and 87% of pharmaceutical executives reported altering R&D or launch plans, including shifting away from Medicare-reliant indications and early-stage small-molecule programs. These trends suggest potential long-term reductions in oral and other small-molecule treatment options for elderly and chronic-disease populations, despite near-term improvements in affordability under Medicare Part D caps.
CONCLUSIONS: Early post-IRA signals indicate that shorter effective exclusivity for small molecules is associated with sizeable reductions in small-molecule investment and post-approval research and strategic shifts away from small-molecule pipelines. Policymakers may need to consider adjustments, such as harmonizing negotiation timelines across modalities, to preserve incentives for small-molecule innovation while maintaining Medicare affordability goals.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HPR139
Topic
Health Policy & Regulatory
Topic Subcategory
Insurance Systems & National Health Care, Pricing Policy & Schemes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, STA: Multiple/Other Specialized Treatments